keyword
MENU ▼
Read by QxMD icon Read
search

HBV DNA

keyword
https://www.readbyqxmd.com/read/29458131/inhibition-of-hepatitis-b-virus-replication-via-hbv-dna-cleavage-by-cas9-from-staphylococcus-aureus
#1
Yu Liu, Miaoxian Zhao, Mingxing Gong, Ying Xu, Cantao Xie, Haohui Deng, Xueying Li, Hongkai Wu, Zhanhui Wang
Chronic hepatitis B virus (HBV) infection is difficult to cure due to the presence of covalently closed circular DNA (cccDNA). Accumulating evidence indicates that the CRISPR/Cas9 system effectively disrupts HBV genome, including cccDNA, in vitro and in vivo. However, efficient delivery of CRISPR/Cas9 system to the liver or hepatocytes using an adeno-associated virus (AAV) vector remains challenging due to the large size of Cas9 from Streptococcus pyogenes (Sp). The recently identified Cas9 protein from Staphylococcus aureus (Sa) is smaller than SpCas9 and thus is able to be packaged into the AAV vector...
February 16, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29455185/performance-evaluation-of-cobas-hbv-real-time-pcr-assay-on-roche-cobas-4800-system-in-comparison-with-cobas-ampliprep-cobas-taqman-hbv-test
#2
Hanah Kim, Mina Hur, Eunsin Bae, Kyung-A Lee, Woo-In Lee
BACKGROUND: Hepatitis B virus (HBV) nucleic acid amplification testing (NAAT) is important for the diagnosis and management of HBV infection. We evaluated the analytical performance of the cobas HBV NAAT (Roche Diagnostics GmbH, Mannheim, Germany) on the cobas 4800 System in comparison with COBAS AmpliPrep/COBAS TaqMan HBV Test (CAP/CTM HBV). METHODS: Precision was evaluated using three levels of cobas HBV/HCV/HIV-1 Control Kit, and linearity was evaluated across the anticipated measuring range (10...
February 19, 2018: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/29453971/prediction-value-of-serum-hbv-large-surface-protein-in-different-phases-of-hbv-infection-and-virological-response-of-chronic-hepatitis-b-patients
#3
Can Liu, Wennan Wu, Hongyan Shang, Sheng Lin, Zhen Xun, Er Huang, Jinpiao Lin, Bin Yang, Qishui Ou
BACKGROUND: Serum HBV large surface protein (HBV-LP) is an envelope protein that has a close relationship with HBV DNA level. This study is to explore the prediction value of HBV-LP in different phase of HBV infection and during antiviral therapy in chronic hepatitis B (CHB) patients. METHODS: A retrospective study was conducted in 2033 individuals, which included 1677 HBV infected patients in different phases and 356 healthy controls. HBV-LP, HBV serum markers and HBV DNA were detected by ELISA, CMIA and qRT-PCR, respectively...
February 14, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29453915/efficacy-of-nucleoside-analogues-for-hepatitis-b-virus-related-liver-failure-a-network-meta-analysis
#4
Jian Wu, Fang Yin, Xinmin Zhou
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir...
March 1, 2018: Acta Pharmaceutica
https://www.readbyqxmd.com/read/29453472/prevalence-of-hepatitis-d-among-patients-with-hepatitis-b-viral-infection-attending-a-tertiary-care-centre-of-nepal
#5
Kiran Regmi, Jeetendra Kaji Shrestha, Sudhamshu Kc, Bikash Jaishi, Niyanta Karki, Dipendra Khadka, Sandip Khadka
INTRODUCTION: Worldwide there is variation in prevalence of Hepatitis D viral infection. Superinfection and co infection with hepatitis B viral infection is known to occur in 15-20 million people. METHODS: This was a descriptive cross-sectional hospital based study carried out in NAMS, Bir hospital, Kathmandu, Nepal from period of January 2017 to June 2017. Consecutive patients of chronic hepatitis B viral infection of HBsAg positive with more than two-time upper normal limit of ALT were enrolled and tested for HDV IgG...
October 2017: JNMA; Journal of the Nepal Medical Association
https://www.readbyqxmd.com/read/29453099/impact-of-integrated-viral-dna-on-the-goal-to-clear-hepatitis-b-surface-antigen-with-different-therapeutic-strategies
#6
REVIEW
Magnus Lindh, Gustaf E Rydell, Simon B Larsson
A hallmark of hepatitis B virus (HBV) infection is the presence of hepatitis B surface antigen (HBsAg) in the serum of patients. Sustained loss of HBV DNA and HBsAg from the blood are main goals for treatment, and considered as functional cure. It is rarely achieved with long-term nucleoside analogue treatment though, both because cccDNA, the template for viral replication, is not completely cleared, and probably also because hepatocytes with HBV DNA integrated into their chromosomes persist and continue to produce large amounts of HBsAg...
February 13, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29453098/control-of-viral-transcripts-as-a-concept-for-future-hbv-therapies
#7
REVIEW
Christoph Seeger
Chronic hepatitis B virus infections affect over 250 million people world-wide, and, at present, are not curable. Of those, over 800000 are expected to die yearly from complications including cirrhosis and primary hepatocellular carcinoma (HCC). A viral episomal DNA intermediate, covalently closed circular DNA (cccDNA) can persist in nuclei of infected hepatocytes and trigger production of infectious virus. Current standard of care treatments against chronic HBV infections primarily rely on nucleoside analogs (NA) that inhibit de novo virus production by inhibiting the viral reverse transcriptase and, as a consequence, reducing virus titers...
February 13, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29452204/antiviral-therapy-in-hepatitis-b-virus-infected-children-with-immune-tolerant-characters-a-pilot-open-lable-randomized-study
#8
Shishu Zhu, Hongfei Zhang, Yi Dong, Limin Wang, Zhiqiang Xu, Weiwei Liu, Yu Gan, Hongmei Tang, Dawei Chen, Fuchuan Wang, Pan Zhao
BACKGROUND & AIM: Chronic infection with hepatitis B virus (HBV) in children possesses a serious health problem worldwide. It remains unresolved how children with immune-tolerant chronic hepatitis B should be treated, who were commonly characterized by HBeAg positivity, high viral load, normal or mildly elevated ALT and no or minimal inflammation in liver histology. This trial aims to study the benefits of antiviral therapy in children with these characters. METHODS: This is a pilot open-lable randomized controlled study...
February 13, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29451182/host-genetic-factors-in-predicting-response-status-in-chronic-hepatitis-b-patients-discontinuing-nucleos-t-ide-analogs
#9
Tao Li, Feng Liu, Lixin Zhang, Qian Ye, Xiaoping Fan, Yan Xue, Lei Wang
Background/Aims: The optimal duration of nucleos(t)ide analogs (NAs) therapy in chronic hepatitis B (CHB) patients remains unsatisfactory. Previous studies have confirmed the important role of host genetic factors in determining the outcome of HBV infection. This study tries to determine the role of host genetic factors in predicting response status in CHB patients discontinuing NAs according to stringent cessation criteria. Patients and Methods: Participating patients came from a prospective NAs- discontinuation cohort since June 1999...
January 2018: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/29447911/fluorescent-protein-tagged-hepatitis-b-virus-capsid-protein-with-long-glycine-serine-linker-that-supports-nucleocapsid-formation
#10
Jiang-Yan Chen, Chun-Yang Gan, Xue-Fei Cai, Wen-Lu Zhang, Quan-Xin Long, Xia-Fei Wei, Yuan Hu, Ni Tang, Juan Chen, Haitao Guo, Ai-Long Huang, Jie-Li Hu
Fusion core proteins of Hepatitis B virus can be used to study core protein functions or capsid trafficking. A problem in constructing fusion core proteins is functional impairment of the individual domains in these fusion proteins, might due to structural interference. We reported a method to construct fusion proteins of Hepatitis B virus core protein (HBc) in which the functions of fused domains were partially kept. This method follows two principles: (1) fuse heterogeneous proteins at the N terminus of HBc; (2) use long Glysine-serine linkers between the two domains...
February 12, 2018: Journal of Virological Methods
https://www.readbyqxmd.com/read/29446468/prevalence-of-occult-hepatitis-b-in-a-population-from-the-brazilian-amazon-region
#11
Carla de Castro Sant' Anna, Marcella Kelly Costa de Almeida, Patrícia Ferreira, Roseane Gomes de Oliveira, Anna Rafaella Ferreira Baraúna, Evonnildo Costa Gonçalvez, Andrea Marinho da Silva, Carolina de Souza Pereira, Luisa Carício Martins
In the present study, we evaluated the prevalence of occult hepatitis B (OBI) in a population from the Brazilian Amazon region, identify circulating genotypes and mutations in the S gene. 181 patients with negative serology for HBsAg and anti-HBs and positive serology for anti-HBc participated in the study. Detection of viral DNA, genotyping by sequencing and analysis of nucleotide sequences to detect possible mutations were performed. HBV DNA was detected in 14.36% of the patients. Genotyping revealed genotype A in 88...
February 15, 2018: Journal of Medical Virology
https://www.readbyqxmd.com/read/29441587/transfusion-transmitted-hepatitis-b-virus-hbv-infection-from-an-individual-donation-nucleic-acid-id-nat-non-reactive-donor
#12
N O'Flaherty, I Ushiro-Lumb, L Pomeroy, S Ijaz, F Boland, C De Gascun, J Fitzgerald, J O'Riordan
Lookback was initiated upon notification of an acute HBV infection in a repeat Irish donor, 108 days post-donation. The donation screened non-reactive by individual-donation nucleic acid testing (ID-NAT) using the Procleix Ultrio Elite multiplex assay and again when the archived sample was retested, but the discriminatory assay for HBV was reactive. The immunocompromised recipient of the implicated red cell component was tested 110 days post-transfusion, revealing a HBV DNA viral load of 470 IU/ml. Genotype C2 sequences identical across two regions of the HBV genome were found in samples from the donor and recipient...
February 14, 2018: Vox Sanguinis
https://www.readbyqxmd.com/read/29435047/gtsf1-gene-may-serve-as-a-novel-potential-diagnostic-biomarker-for-liver-cancer
#13
De-Yong Gao, Yun Ling, Xiao-Li Lou, Ying-Ying Wang, Liang-Ming Liu
The gametocyte-specific factor 1 (GTSF1) gene participates in DNA methylation and retrotransposon activation in germ cells, particularly during cell proliferation. The present study aimed to assess the level of GTSF1 gene expression in liver cancer tumor tissues, and its role in human hepatoma cell lines in vitro and in a nude mouse model in vivo. GTSF1 gene expression was detected in liver cancer tumor tissues, compared with in healthy controls, via reverse transcription quantitative polymerase chain reaction...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434654/quasispecies-variant-of-pre-s-s-gene-in-hbv-related-hepatocellular-carcinoma-with-hbs-antigen-positive-and-occult-infection
#14
Yuri Hatazawa, Yoshihiko Yano, Rina Okada, Toshihito Tanahashi, Hiroki Hayashi, Hirotaka Hirano, Akihiro Minami, Yuki Kawano, Motofumi Tanaka, Takumi Fukumoto, Yoshiki Murakami, Masaru Yoshida, Yoshitake Hayashi
Background: Hepatocellular carcinoma (HCC) can develop in patients who are negative for the hepatitis B surface antigen (HBsAg) in serum but positive for hepatitis B virus (HBV) DNA in the liver, referred to as occult HBV infection (OBI). Previous reports showed that HBV variants in OBI-related HCC are different from those in HBsAg-positive HCC. In the present study, HBV quasispecies based on the pre-S/S gene in OBI-related HCC patients were examined by high throughput sequencing and compared with those in HBsAg-positive HCC...
2018: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/29432906/hepatitis-b-virus-x-protein-and-proinflammatory-cytokines-synergize-to-enhance-trail-induced-apoptosis-of-renal-tubular-cells-by-upregulation-of-dr4
#15
Yitong Yang, Xuan Wang, Yueyue Zhang, Weijie Yuan
Persistent infection with hepatitis B virus (HBV) may lead to HBV-associated glomerulonephritis (HBV-GN). Presence of HBV-DNA and -RNA in renal tubular epithelial cells (RTECs) suggests direct virus-induced injury. Increase in proinflammatory cytokines is also observed under these conditions. Apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) plays a significant role in the pathogenesis of HBV-infections. However, the effects of HBV X protein (HBx) on TRAIL-induced apoptosis of RTECs especially under certain inflammatory conditions remain obscure...
February 9, 2018: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/29432880/prevalence-of-hepatitis-b-virus-and-hepatitis-d-virus-coinfection-in-western-burkina-faso-and-molecular-characterization-of-the-detected-virus-strains
#16
Armel M Sanou, Kenza Benkirane, Bachirou Tinto, Assana Cissé, Tani Sagna, Abdoul Kader Ilboudo, Claire Dording, Zekiba Tarnagda, Claude P Muller, Judith M Hübschen
OBJECTIVES: In this study, we monitored the seroprevalence of HBV-HDV co-infection in different population groups in the Western part of Burkina Faso, and described the genetic diversity of the detected virus strains. METHODS: Between October 2013 and December 2014, venous blood samples were collected from different cohorts (blood donors, pregnant women, outpatients) in the western region of Burkina Faso. Samples were tested for HBsAg and total anti-HDV antibodies...
February 9, 2018: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/29432776/establishment-of-cre-mediated-hbv-recombinant-cccdna-rcccdna-cell-line-for-cccdna-biology-and-antiviral-screening-assays
#17
Min Wu, Jin Li, Lei Yue, Lu Bai, Yaming Li, Jieliang Chen, Xiaonan Zhang, Zhenghong Yuan
Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA), existing in hepatocyte nuclei as a stable minichromosome, plays a central role in the life cycle of the virus and permits the persistence of infection. Despite being essential for HBV infection, little is known about the molecular mechanisms of cccDNA formation, regulation and degradation, and there is no therapeutic agents directly targeting cccDNA, fore mostly due to the lack of robust, reliable and quantifiable HBV cccDNA models. In this study, combined the Cre/loxP and sleeping beauty transposons system, we established HepG2-derived cell lines integrated with 2-60 copies of monomeric HBV genome flanked by loxP sites (HepG2-HBV/loxP)...
February 9, 2018: Antiviral Research
https://www.readbyqxmd.com/read/29427498/treatment-of-hepatitis-b-is-there-still-a-role-for-interferon
#18
REVIEW
Mauro Viganò, Glenda Grossi, Alessandro Loglio, Pietro Lampertico
The treatment of chronic hepatitis B (CHB) patients is based on monotherapy with pegylated-interferon (Peg-IFN) or with one of the three most potent nucleot(s)ide analogues (NUCs) with the best resistance profiles, i.e. entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF). Long-term NUCs treatment can achieve virological suppression in almost all patients. However, this requires lifelong therapy, is costly and the rate of hepatitis B surface antigen (HBsAg) seroclearance is low...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29427495/hepatitis-b-who-and-when-to-treat
#19
REVIEW
Jiannis Vlachogiannakos, George V Papatheodoridis
As current treatment options almost never achieve eradication of hepatitis B virus (HBV), the most realistic goal for HBV treatment is persistent inhibition of viral replication and ALT normalization. Thus, the decision to start treatment should be based on careful patient selection and individualized decisions. Treatment is generally indicated in chronic hepatitis B patients with HBV DNA >2000 IU/mL, elevated ALT and/or at least moderate histological lesions, while all patients with cirrhosis and detectable HBV DNA should be treated...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29427489/stopping-long-term-treatment-with-nucleos-t-ide-analogues-is-a-favourable-option-for-selected-patients-with-hbeag-negative-chronic-hepatitis-b
#20
REVIEW
Florian van Bömmel, Thomas Berg
The immune response against the infection is impaired in patients with chronic hepatitis B, and although HBV DNA can effectively be suppressed by nucleos(t)ide analogues (NA), durable immune control is only established in a minority of patients. This especially applies in HBeAg-negative patients who usually must receive lifelong NA treatment. Calculated withdrawal of NA leads to a relapse of HBV DNA in most patients. There is evidence that this sudden exposure of viral antigens can trigger immune control in some patients which may result in HBsAg loss or a form of immune control, then sustained low HBV DNA levels and normal alanine aminotransferase (ALT)...
February 2018: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
53389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"